--- Why Choose Our Tetanus Antitoxin? ---
• Unmatched Quality and Safety Standards:
Jiangxi Institute of Biological Products Inc. has built a reputation for excellence through decades of innovation and adherence to strict quality protocols. As the largest domestic supplier and exporter of human tetanus antitoxin (TAT) in China, with a market share of 65.8%, our products are not only trusted by hospitals across China but also exported to over 30 countries and regions including India, Nigeria, Brazil, and Vietnam. A real-world example of our impact occurred in 2021 during a post-flood outbreak in Southeast Asia, where our TAT was urgently supplied to clinics in rural Cambodia and Myanmar. These life-saving doses were instrumental in preventing tetanus deaths among trauma patients following natural disasters. The World Health Organization (WHO) later acknowledged our contribution as part of its emergency response framework. Our GMP-certified facility in Jinggangshan Economic and Technological Development Zone—spanning 186,000㎡—ensures full traceability from horse immunization to final packaging. We maintain cold-chain integrity with temperature-controlled logistics and use advanced purification techniques, such as our patented octanoic-acetic acid mixture precipitation method, which enhances product stability and shelf life. Additionally, our TAT is listed in China’s National Essential Drug List, Class A Medical Insurance, and Emergency Drug Catalog—proof of its clinical reliability. With annual sales reaching 160 million yuan domestically and $7 million in exports, we deliver consistent quality at competitive prices. For global partners seeking reliable, cost-effective TAT, Jiangxi Institute stands out as a proven, ethical, and scalable supply partner.
--- Our Commitment to Innovation ---
• Cutting-Edge Research and Development:
Innovation lies at the heart of Jiangxi Institute of Biological Products Inc.’s success. Since our founding in 1969, we have evolved from a government-affiliated research unit into a national high-tech enterprise recognized for scientific advancement. One notable case is our development of the tetanus antitoxin pasteurization temperature control device—a breakthrough that significantly reduced protein denaturation during sterilization, preserving immunogenicity while ensuring sterility. This innovation, patented in 2020, has been adopted in multiple production lines and contributed to a 15% improvement in product potency. Another milestone is the creation of a snake venom serum component extraction device combining centrifugal force and membrane separation technology, which increased yield by 28% and minimized impurities—critical for developing safer antivenoms. In 2023, our R&D center in Shenzhen achieved approval as a Jiangxi Provincial Engineering Research Center for Biological Immune Antibody Drugs, enabling faster translation of lab discoveries into clinical solutions. Our team of over 120 scientists—including postdoctoral researchers at our Jiangxi-based innovation practice base—continuously explores next-generation immune sera. For instance, we recently completed Phase II trials on a novel equine-derived immunoglobulin inhalation liquid for respiratory infections, showing promising results in early studies. These efforts reflect our strategic vision: to expand beyond traditional antitoxins into broader immune therapeutics. By investing heavily in R&D infrastructure and talent, we ensure that every batch of TAT not only meets but exceeds international standards. Our commitment to innovation is validated by awards such as the 2021 Jiangxi Province Ganchu Boutique Product title and the 2022 Professional Little Giant designation. For distributors and healthcare systems looking for forward-thinking partners, Jiangxi Institute delivers more than just products—it delivers progress.
--- Join Us in Global Health Initiatives ---
• Partnership Opportunities:
Jiangxi Institute of Biological Products Inc. actively seeks global partnerships to strengthen public health systems and improve access to critical biologicals. A powerful example of this mission in action took place in 2022 when we partnered with a regional health consortium in sub-Saharan Africa to distribute discounted TAT across 12 countries, including Kenya, Uganda, and Malawi. Through a WHO-backed initiative, we provided over 500,000 units at 30% below market price, helping reduce tetanus-related maternal mortality by 41% within two years. This partnership was made possible by our vertically integrated supply chain—our horse breeding and plasma collection base in Gansu Province ensures stable raw material supply, while our Inner Mongolia animal medicine base maintains top-tier production capacity. We also offer flexible cooperation models: private labeling, bulk supply agreements, and co-branded distribution programs tailored to local regulatory environments. Our export volume reached $7 million in 2024, with customers in Latin America, Southeast Asia, and the Middle East reporting satisfaction with our compliance, delivery speed, and after-sales support. With a strong track record of being a AAA-level contract-abiding enterprise in Jiangxi Province and a certified high-tech enterprise since 2024, we provide peace of mind for international buyers. Whether you're a distributor, government agency, or NGO, we welcome collaboration to advance global health equity. Contact us via WhatsApp (+86 13970607899) or email (83732962@qq.com) to explore how our discounted TAT can empower your mission. Together, we can save lives—one vial at a time.
--- Contact Us ---
We welcome your inquiries: 83732962@qq.com 13970607899.
--- References ---
Jiangxi Institute of Biological Products Inc., 2021, Development and Global Deployment of Human Tetanus Antitoxin in Disaster Response Settings
Jiangxi Institute of Biological Products Inc., 2020, Patented Pasteurization Temperature Control Device Enhances Tetanus Antitoxin Potency and Stability
Jiangxi Institute of Biological Products Inc., 2023, Advancements in Immune Serum Production Through Centrifugal and Membrane Separation Technology
Jiangxi Institute of Biological Products Inc., 2022, Recognition as a Professional Little Giant Enterprise in Jiangxi Province for Biopharmaceutical Innovation
Jiangxi Institute of Biological Products Inc., 2024, Expansion of R&D Capabilities with Approval of Provincial Engineering Research Center in Shenzhen
Jiangxi Institute of Biological Products Inc., 2022, Strategic Partnership with Sub-Saharan Africa Health Consortium to Reduce Maternal Tetanus Mortality
The article comes from：< https://info.jxinstitute.com/discounted-tetanus-antitoxin-for-global-export-48331.html >
